Limits...
Impact of comorbidities and use of common medications on cancer and non-cancer specific survival in esophageal carcinoma.

He LR, Qiao W, Liao ZX, Komaki R, Ho L, Hofstetter WL, Lin SH - BMC Cancer (2015)

Bottom Line: Seven kinds of frequently occurring chronic comorbidities and 18 types of regularly-taken medications were obtained from medical records.Overall mortality, EC-specific mortality and non EC-specific mortality were endpoints.Comorbidity information may better guide individual treatment in EC.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, Cancer Center, Sun Yat-Sun University, Guangzhou, China, helir@sysucc.org.cn.

ABSTRACT

Background: Chronic comorbidities and some of the commonly-used medications are thought to affect cancer patients' outcomes, but their relative impact on esophageal carcinoma (EC) has not been well studied. The purpose of the study was to identify the chronic comorbidities and/or commonly-used medications that impact EC patient survival.

Methods: A total of 1174 EC patients treated with chemoradiotherapy (CRT) with or without surgery in one institution from 1998 to 2012 were retrospectively included. Seven kinds of frequently occurring chronic comorbidities and 18 types of regularly-taken medications were obtained from medical records. Since it is expected prognostic factors have different effects between surgery patients and non-surgery patients, the impact value of all variables and the corresponding interactions with surgery on survival were evaluated in Cox proportional hazards regression model. Overall mortality, EC-specific mortality and non EC-specific mortality were endpoints.

Results: We found that atrial fibrillation was the only comorbidity that showed a significant impact on non-EC specific survival for all patients (HR 1.72, P = 0.03), whereas hypothyroidism was the only comorbidity that was evaluated as an independent predictive factor for overall survival (OS) (HR 0.59, P = 0.02) and EC-specific survival (HR 0.62, P = 0.05), but this association was seen only in the non-surgical patients. No other medications were found to have a significant impact for OS, EC-specific survival or non-EC specific survival in multivariable analysis.

Conclusions: Our data indicate that certain comorbidities rather than medication use affect EC-specific survival or non EC-specific survival in EC patients treated with CRT with or without surgery. Comorbidity information may better guide individual treatment in EC.

Show MeSH

Related in: MedlinePlus

Survival stratified by hypothyroidism and surgery status for patients with esophageal carcinoma. A: Overall survival, B: Esophageal carcinoma-specific survival.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4359440&req=5

Fig2: Survival stratified by hypothyroidism and surgery status for patients with esophageal carcinoma. A: Overall survival, B: Esophageal carcinoma-specific survival.

Mentions: To better interpret the significant interaction of hypothyroidism/levothyroxine and surgery for OS and EC-specific survival, the survival curves stratified by hypothyroidism/levothyroxine and surgery were further presented in Figure 2A and B. The 5 year OS (45% vs. 25%, P = 0.003) and EC-specific survival (62% vs. 38%, P = 0.004) for patients with hypothyroidism/levothyroxine was significant higher than those without hypothyroidism/levothyroxine for non-surgery patients but not for surgery patients (P > 0.05).Figure 2


Impact of comorbidities and use of common medications on cancer and non-cancer specific survival in esophageal carcinoma.

He LR, Qiao W, Liao ZX, Komaki R, Ho L, Hofstetter WL, Lin SH - BMC Cancer (2015)

Survival stratified by hypothyroidism and surgery status for patients with esophageal carcinoma. A: Overall survival, B: Esophageal carcinoma-specific survival.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4359440&req=5

Fig2: Survival stratified by hypothyroidism and surgery status for patients with esophageal carcinoma. A: Overall survival, B: Esophageal carcinoma-specific survival.
Mentions: To better interpret the significant interaction of hypothyroidism/levothyroxine and surgery for OS and EC-specific survival, the survival curves stratified by hypothyroidism/levothyroxine and surgery were further presented in Figure 2A and B. The 5 year OS (45% vs. 25%, P = 0.003) and EC-specific survival (62% vs. 38%, P = 0.004) for patients with hypothyroidism/levothyroxine was significant higher than those without hypothyroidism/levothyroxine for non-surgery patients but not for surgery patients (P > 0.05).Figure 2

Bottom Line: Seven kinds of frequently occurring chronic comorbidities and 18 types of regularly-taken medications were obtained from medical records.Overall mortality, EC-specific mortality and non EC-specific mortality were endpoints.Comorbidity information may better guide individual treatment in EC.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, Cancer Center, Sun Yat-Sun University, Guangzhou, China, helir@sysucc.org.cn.

ABSTRACT

Background: Chronic comorbidities and some of the commonly-used medications are thought to affect cancer patients' outcomes, but their relative impact on esophageal carcinoma (EC) has not been well studied. The purpose of the study was to identify the chronic comorbidities and/or commonly-used medications that impact EC patient survival.

Methods: A total of 1174 EC patients treated with chemoradiotherapy (CRT) with or without surgery in one institution from 1998 to 2012 were retrospectively included. Seven kinds of frequently occurring chronic comorbidities and 18 types of regularly-taken medications were obtained from medical records. Since it is expected prognostic factors have different effects between surgery patients and non-surgery patients, the impact value of all variables and the corresponding interactions with surgery on survival were evaluated in Cox proportional hazards regression model. Overall mortality, EC-specific mortality and non EC-specific mortality were endpoints.

Results: We found that atrial fibrillation was the only comorbidity that showed a significant impact on non-EC specific survival for all patients (HR 1.72, P = 0.03), whereas hypothyroidism was the only comorbidity that was evaluated as an independent predictive factor for overall survival (OS) (HR 0.59, P = 0.02) and EC-specific survival (HR 0.62, P = 0.05), but this association was seen only in the non-surgical patients. No other medications were found to have a significant impact for OS, EC-specific survival or non-EC specific survival in multivariable analysis.

Conclusions: Our data indicate that certain comorbidities rather than medication use affect EC-specific survival or non EC-specific survival in EC patients treated with CRT with or without surgery. Comorbidity information may better guide individual treatment in EC.

Show MeSH
Related in: MedlinePlus